We are live on ! Find out more
DMKJ

David M. Knott Jr Portfolio holdings

AUM $189M Turnover 22.11%
1-Year Est. Return 67.72%
This Fund
S&P 500
This Quarter Est. Return
+1.58%
1 Year Est. Return
+67.72%
3 Year Est. Return
+169.37%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$251M
AUM Growth
-$32.1M
Cap. Flow
-$32.3M
Cap. Flow %
-12.88%
Top 10 Hldgs %
68.46%
Holding
112
New
6
Increased
15
Reduced
10
Closed
13
Avg Time Held
1.6 years
Top 10 Avg Time Held
1.4 years
Top 20 Avg Time Held
1.2 years

Top Buys

Rank Stock Value
1
DCGO icon
DocGo
DCGO
+$3.77M
2
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$1.73M
3
VRNA
Verona Pharma
VRNA
+$1.28M
4
SNDX icon
Syndax Pharmaceuticals
SNDX
+$803K
5
MREO icon
Mereo BioPharma
MREO
+$667K

Top Sells

Rank Stock Value
1
FTAI icon
FTAI Aviation
FTAI
+$16.8M
2
WEST icon
Westrock Coffee
WEST
+$4.89M
3
CLOZ icon
Panagram BBB-B CLO ETF
CLOZ
+$4.73M
4
JAAA icon
Janus Henderson AAA CLO ETF
JAAA
+$3.64M
5
LGND icon
Ligand Pharmaceuticals
LGND
+$2.39M

Sector Composition

Rank Sector Weight
1 Healthcare 30.74%
2 Materials 28.51%
3 Financials 14.16%
4 Miscellaneous 12.73%
5 Communication Services 8.23%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
LK
26
DELISTED
Luckin Coffee Inc. American Depositary Shares
LK
$2.11M 0.84%
100,000
– –
2024 Q1
1 quarter
BCRX icon
27
BioCryst Pharmaceuticals
BCRX
$2.05B
$1.94M 0.77%
+314,307
New +$1.73M
2024 Q2
0 quarters
XERS icon
28
Xeris Biopharma Holdings
XERS
$1.84B
$1.84M 0.74%
820,000
+220,000
+37% +$443K
2023 Q4
2 quarters
PTGX icon
29
Protagonist Therapeutics
PTGX
$8.84B
$1.81M 0.72%
52,368
– –
2023 Q3
3 quarters
AB icon
30
AllianceBernstein
AB
$3.2B
$1.66M 0.66%
49,000
– –
2021 Q4
10 quarters
VRTX icon
31
Vertex Pharmaceuticals
VRTX
$129B
$1.41M 0.56%
3,000
– –
2021 Q4
10 quarters
XBI icon
32
State Street SPDR S&P Biotech ETF
XBI
$9.9B
$1.3M 0.52%
14,000
-2,000
-13% -$179K
2023 Q4
2 quarters
RHP icon
33
Ryman Hospitality Properties
RHP
$8.65B
$1.2M 0.48%
12,000
– –
2021 Q4
10 quarters
EOLS icon
34
Evolus
EOLS
$500M
$1.18M 0.47%
108,682
+28,682
+36% +$353K
2023 Q1
5 quarters
MDLZ icon
35
Mondelez International
MDLZ
$80.4B
$916K 0.37%
14,000
– –
2021 Q4
10 quarters
ABBV icon
36
AbbVie
ABBV
$501B
$864K 0.34%
5,037
– –
2021 Q4
10 quarters
MREO icon
37
Mereo BioPharma
MREO
$49.4M
$850K 0.34%
236,000
+206,000
+687% +$667K
2024 Q1
1 quarter
KMB icon
38
Kimberly-Clark
KMB
$34.6B
$829K 0.33%
6,000
– –
2021 Q4
10 quarters
EDIT icon
39
Editas Medicine
EDIT
$375M
$827K 0.33%
177,000
+37,000
+26% +$209K
2024 Q1
1 quarter
XENE icon
40
Xenon Pharmaceuticals
XENE
$3.32B
$814K 0.32%
20,866
-3,000
-13% -$120K
2021 Q4
10 quarters
DD icon
41
DuPont de Nemours
DD
$17.8B
$799K 0.32%
7,911
– –
2021 Q4
10 quarters
MSFT icon
42
Microsoft
MSFT
$4.01T
$715K 0.29%
1,600
– –
2021 Q4
10 quarters
ROIV icon
43
Roivant Sciences
ROIV
$24.6B
$666K 0.27%
63,000
+9,800
+18% +$107K
2023 Q4
2 quarters
CTVA icon
44
Corteva
CTVA
$8.59B
$624K 0.25%
11,563
– –
2021 Q4
10 quarters
CNQ icon
45
Canadian Natural Resources
CNQ
$107B
$598K 0.24%
16,800
– –
2021 Q4
10 quarters
DOW icon
46
Dow Inc
DOW
$21.4B
$591K 0.24%
11,136
– –
2021 Q4
10 quarters
BBIO icon
47
BridgeBio Pharma
BBIO
$13.1B
$532K 0.21%
21,000
+5,000
+31% +$137K
2023 Q3
3 quarters
AAPL icon
48
Apple
AAPL
$4.99T
$525K 0.21%
2,494
– –
2021 Q4
10 quarters
CLOX icon
49
Panagram AAA CLO ETF
CLOX
$337M
$500K 0.2%
19,572
-73,384
-79% -$1.87M
2023 Q3
3 quarters
KO icon
50
Coca-Cola
KO
$396B
$484K 0.19%
7,600
– –
2021 Q4
10 quarters
1
2
3 4 5

Similar funds

SCA
Sander Capital Advisors Seattle, Washington $189M AUM 13.06% 1-Year Est. Return
FI
FWG Investments Lexington, Kentucky $189M AUM 18.47% 1-Year Est. Return
MFS
Madrid Financial Services Manhattan Beach, California $189M AUM 30.12% 1-Year Est. Return
FRA
FFG Retirement Advisors Centennial, Colorado $189M AUM 16.39% 1-Year Est. Return
CAM
Councilmark Asset Management Knoxville, Tennessee $189M AUM 26.93% 1-Year Est. Return
BAG
Bauman Advisory Group Las Vegas, Nevada $189M AUM
SHC
SALT Holding Corp Wilmington, Delaware $189M AUM 34.63% 1-Year Est. Return
HC
Hara Capital Bellevue, Washington $190M AUM 42.56% 1-Year Est. Return

David M. Knott Jr's Q2 2024 Portfolio in Review

As of Q2 2024, David M. Knott Jr held 112 positions worth $251M, down 11% from $283M the previous quarter. Its ten largest holdings account for 68% of the portfolio.

David M. Knott Jr withdrew a net $32.3M in Q2 2024, closing 13 positions and reducing 10 holdings. Its most notable exit was FTAI Aviation, an estimated $16.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 31% of assets, up from 30% a quarter earlier, followed by Materials and Financials.

Against the trend, David M. Knott Jr opened a new position in BioCryst Pharmaceuticals worth $1.94M.

  • David M. Knott Jr's largest Q2 2024 buy was BioCryst Pharmaceuticals: 314,307 shares worth $1.94M.
  • David M. Knott Jr added most to DocGo in Q2 2024, an estimated $3.77M increase.
  • David M. Knott Jr's biggest Q2 2024 reduction was Panagram BBB-B CLO ETF, cutting an estimated $4.73M.
  • David M. Knott Jr fully exited FTAI Aviation in Q2 2024, selling an estimated $16.8M.
  • David M. Knott Jr's ten largest holdings make up 68% of its $251M portfolio in Q2 2024.
  • David M. Knott Jr opened 6 new positions and closed 13 in Q2 2024.
  • David M. Knott Jr's portfolio value fell 11% quarter-over-quarter to $251M.

Based on David M. Knott Jr's 13F filing for Q2 2024, filed 12 Aug 2024.